[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022006026A - Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos. - Google Patents

Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos.

Info

Publication number
MX2022006026A
MX2022006026A MX2022006026A MX2022006026A MX2022006026A MX 2022006026 A MX2022006026 A MX 2022006026A MX 2022006026 A MX2022006026 A MX 2022006026A MX 2022006026 A MX2022006026 A MX 2022006026A MX 2022006026 A MX2022006026 A MX 2022006026A
Authority
MX
Mexico
Prior art keywords
synuclein
monoclonal antibodies
methods
antibodies
alpha
Prior art date
Application number
MX2022006026A
Other languages
English (en)
Inventor
Kelvin C Luk
Virginia M Y Lee
John Q Trojanowski
Kurt R Brunden
Dustin Covell
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2022006026A publication Critical patent/MX2022006026A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente descripción proporciona anticuerpos monoclonales que se unen a la a sinucleína; en ciertos aspectos, los anticuerpos se unen preferentemente a las fibrillas de a-sinucleína sobre el monómero de a-sinucleína; en otros aspectos, la descripción proporciona un método para tratar, mejorar y/o prevenir la enfermedad a-sinucleopática en un sujeto, que comprende administrar cualquiera de los anticuerpos de la descripción al sujeto; en otros aspectos más, la descripción proporciona métodos para detectar fibrillas de a-sinucleína utilizando cualquiera de los anticuerpos de la descripción.
MX2022006026A 2019-11-19 2020-11-19 Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos. MX2022006026A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937636P 2019-11-19 2019-11-19
PCT/US2020/061376 WO2021102197A1 (en) 2019-11-19 2020-11-19 Anti-alpha-synuclein monoclonal antibodies, and methods using same

Publications (1)

Publication Number Publication Date
MX2022006026A true MX2022006026A (es) 2022-09-12

Family

ID=75981490

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006026A MX2022006026A (es) 2019-11-19 2020-11-19 Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos.

Country Status (9)

Country Link
US (1) US20230025707A1 (es)
EP (1) EP4061840A4 (es)
JP (1) JP2023502122A (es)
CN (1) CN114945592A (es)
AU (1) AU2020386061A1 (es)
CA (1) CA3158364A1 (es)
IL (1) IL293108A (es)
MX (1) MX2022006026A (es)
WO (1) WO2021102197A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696620B2 (en) * 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
ES2856451T3 (es) * 2005-10-11 2021-09-27 Amgen Res Munich Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法
CN103627676A (zh) * 2013-05-10 2014-03-12 深圳大学 多头绒泡菌14-3-3蛋白单克隆抗体及其制备方法
WO2015089117A1 (en) * 2013-12-09 2015-06-18 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3618870A4 (en) * 2017-05-01 2021-04-21 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST ALPHA-SYNUCLEIN FIBRILLES
EP3661961A4 (en) * 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
EP3672635A4 (en) * 2017-08-23 2021-05-12 The Trustees of The University of Pennsylvania MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN, AND METHODS USING THEM
CN110172098B (zh) * 2019-05-27 2023-03-10 长春工业大学 抗α-突触核蛋白的单克隆抗体及其应用

Also Published As

Publication number Publication date
EP4061840A4 (en) 2024-05-15
CN114945592A (zh) 2022-08-26
CA3158364A1 (en) 2021-05-27
JP2023502122A (ja) 2023-01-20
US20230025707A1 (en) 2023-01-26
EP4061840A1 (en) 2022-09-28
IL293108A (en) 2022-07-01
AU2020386061A1 (en) 2022-06-02
WO2021102197A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
NZ782442A (en) Antibodies that bind cd39 and uses thereof
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
MX2018015149A (es) Anticuerpos anti-c5 y usos de los mismos.
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
ZA201905866B (en) Anti-c5 antibodies and uses thereof
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
EA202091482A1 (ru) Антитела
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
EA202091478A1 (ru) Антитела
EA202090673A1 (ru) Стратификация генотипа при лечении и профилактике диабета
MX2022007521A (es) Anticuerpos contra la integrina alfa 11 beta 1.
EA201892071A1 (ru) Способ профилактики болезни "трансплантат против хозяина"
MX2024008740A (es) Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.
MX2022003719A (es) Anticuerpos anti-il-27 y sus usos.
MX2022006026A (es) Anticuerpos monoclonales anti-alfa-sinucleina y metodos que utilizan los mismos.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.